Treating Anemia Earlier in Myelodysplastic Syndromes

Duration of Response Contributes to Survival in COMMANDS Trial in MDS

During a live event, Praneeth Baratam, MBBS, discussed long-term data from a trial comparing luspatercept with epoetin alfa in low-risk myelodysplastic syndromes.

Understanding the Role of Mutations in Staging of Low-Risk MDS

During a live event, Praneeth Baratam, MBBS, discussed the molecular factors that affect staging of lower-risk myelodysplastic syndromes.

Oncologists Choose Top Goals and Therapies for Treating MDS

Luke Fletcher, MD, reviews updates in anemia-predominant MDS and the 2025 polling results from MDS Case-Based Roundtable events.

Outcomes With Luspatercept Not Affected by Mutational Profile in MDS

During a live event, Thomas LeBlanc, MD, MA, discussed dose escalation of luspatercept in myelodysplastic syndromes and response to treatment based on mutational analyses.

Luspatercept Outperforms ESA in Duration of Anemia Response in MDS

During a live event, Thomas LeBlanc, MD, MA, discussed the outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndromes.

Optimizing Anemia Care with Targeted Therapies for Low-Risk MDS

During a live event, Christopher Benton, MD, discussed treatment of myelodysplastic syndromes like luspatercept and imetelstat as alternatives to ESAs.

Improving Quality of Life in LR-MDS Through Anemia Treatment

During a live event, Chris Benton, MD, discussed the focus on anemia management, reducing transfusions, and improving quality of life in MDS.

Transfusion Independence Serves as Key End Point for LR-MDS Trials

Saeed Sadeghi, MD, discusses the findings on transfusion independence achieved with treatment for patients with low-risk myelodysplastic syndrome.

Evaluating Agents to Manage Low-Risk Myelodysplastic Syndrome

Saeed Sadeghi, MD, discusses treatment options in low-risk myelodysplastic syndrome at a Case-Based Roundtable event.

Dose Escalation of Luspatercept Is Underutilized in MDS

Saeed Sadeghi, MD, discusses valuable feedback he heard from oncologists on the use of luspatercept-aamt in patients with low-risk myelodysplastic syndrome.

Therapies With Different Mechanisms of Action Available for Low-Risk MDS

Bertrand Y. Tuan, MD, discusses the therapies relevant to patients with low-risk myelodysplastic syndrome.

Ring Sideroblasts Status Affects Treatment Decisions for Frontline MDS

Amer Zeidan, MBBS, discusses how ring sideroblasts status affects using luspatercept in patients with myelodysplastic syndromes.

COMMANDS Trial Demonstrates Benefit Across Mutations in RS-Positive LR-MDS

During a Case-Based Roundtable® event, Yazan Madanat, MD, discussed a the patient population and outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndrome in the first article of a 2-part series.

Genetics and Ring Sideroblasts Impact ESA-Refractory Anemia in MDS

During a Case-Based Roundtable® event, Azra Raza, MD, discussed a patient case of myelodysplastic syndrome first treated with erythropoiesis-stimulating agent in the second article of a 2-part series.

Luspatercept in MDS Promotes Transfusion Independence and Anemia Response

During a Case-Based Roundtable® event, Azra Raza, MD, discussed a patient case and outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndrome in the first article of a 2-part series.

COMMANDS Trial Shows Positive Result in MDS Despite Pandemic

During a Case-Based Roundtable® event, Amer Zeidan, MBBS, reviewed data for luspatercept-aamt for patients with low-risk myelodysplastic syndrome in the second article of a 2-part series.

COMMANDS Trial Shows Positive Result in MDS Despite Pandemic

During a Case-Based Roundtable® event, Amer Zeidan, MBBS, reviewed data for luspatercept-aamt for patients with low-risk myelodysplastic syndrome in the second article of a 2-part series.

Zeidan Reviews Past Treatment Options for Patient With Lower-Risk MDS

During a Case-Based Roundtable® event, Amer Zeidan, MBBS, discussed how he would have approached a patient with anemia from low-risk myelodysplastic syndrome before the development of newer drugs in the first article of a 2-part series.

Luspatercept Shows Clinically Meaningful Improvement Over ESAs in MDS

Guillermo Garcia-Manero, MD, discusses the design and outcomes of the phase 3 COMMANDS trial in patients with low-risk myelodysplastic syndromes.

Subgroup Analyses of COMMANDS Trial Favor Luspatercept in MDS

Amer Zeidan, MBBS, discusses the primary end point and subgroup analyses performed on the COMMANDS trial of luspatercept-amt for treating anemia in patients with myelodysplastic syndromes.

How the Frontline Indication for Luspatercept Impacts Anemia in MDS

Amer Zeidan, MBBS, discusses the recent expansion of the indication for luspatercept-amt to the frontline setting to treat anemia in patients with lower-risk myelodysplastic syndromes.